Core Viewpoint - Fujian Wancheng Biotechnology Group Co., Ltd. plans to acquire a 49% stake in Nanjing Wanyou Commercial Management Co., Ltd. through cash payment, constituting a major asset restructuring and related party transaction [1] Group 1: Transaction Details - The transaction is expected to increase the company's net profit from 358.58 million yuan to 415.52 million yuan post-transaction, and basic earnings per share from 1.99 yuan to 2.31 yuan [1] - The independent financial advisor, Huaxing Securities, has assessed the potential dilution of immediate returns and proposed measures to mitigate this risk [1][5] Group 2: Measures to Address Dilution - The company will enhance the biological conversion rate of edible fungi cultivation by optimizing processes and improving breeding formulas [2] - The company aims to focus on high-quality development in the bulk snack business, leveraging market influence to improve operational efficiency and profitability [2] - The company will adhere to relevant laws and regulations to optimize governance structures and strengthen internal controls, ensuring the protection of minority shareholders' rights [2] Group 3: Commitments from Stakeholders - The controlling shareholder and actual controller have committed not to interfere with the company's management and to protect its interests [4] - The board of directors and senior management have pledged to diligently fulfill their responsibilities and ensure that their compensation is linked to the execution of measures to mitigate return dilution [4][5] Group 4: Independent Financial Advisor's Opinion - The independent financial advisor believes that the analysis of potential dilution of immediate returns is reasonable and that the measures in place will protect the rights of all shareholders, particularly minority investors [5]
万辰集团: 华兴证券有限公司关于福建万辰生物科技集团股份有限公司本次重大资产重组摊薄即期回报情况及相关填补措施的核查意见